abstract |
The present invention relates to a combination therapy using a tumor-targeted bispecific OX40 antibody (particularly an anti-FAP / anti-OX40 antibody) and a T cell activation anti-CD3 bispecific antibody specific for tumor-associated antigens, and these combinations The use of therapy for the treatment of cancer and methods of using these combination therapies. |